User:Mr. Ibrahem/Cilostazol

Mr. Ibrahem/Cilostazol
Clinical data
Pronunciation	/sɪˈlɒstəzɒl/; sil-OS-tə-zol
Trade names	Pletal
AHFS/Drugs.com	Monograph
MedlinePlus	a601038
License data	US DailyMed: Cilostazol;
Routes of; administration	By mouth (tablets)
Drug class	Phosphodiesterase 3 inhibitor
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Protein binding	95–98%
Metabolism	Liver (CYP3A4- and CYP2C19-mediated)
Elimination half-life	11–13 hours
Excretion	Kidney
Identifiers
	IUPAC name 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-; 3,4-dihydro-2(1H)-quinolinone;
Chemical and physical data
Formula	C20H27N5O2
Molar mass	369.469 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C4Nc3c(cc(OCCCCc1nnnn1C2CCCCC2)cc3)CC4;
	InChI InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26) ; Key:RRGUKTPIGVIEKM-UHFFFAOYSA-N ;
	(verify)

Cilostazol, sold under the brand name Pletal among others, is a medication used to help the symptoms of intermittent claudication in peripheral vascular disease.^[1] If no improvement is seen after 3 months, stopping the medication is reasonable.^[3] It may also be used to prevent stroke.^[1] It is taken by mouth.^[1]

Common side effects include headache, diarrhea, dizziness, and cough.^[1] Serious side effects may include decreased survival in those with heart failure, low platelets, and low white blood cells.^[1] Cilostazol is a phosphodiesterase 3 inhibitor which works by inhibiting platelet aggregation and dilating arteries.^[1]

Cilostazol was approved for medical use in the United States in 1999.^[1] It is available as a generic medication.^[3] A month supply in the United Kingdom costs the NHS about 5 £ as of 2019.^[3] In the United States the wholesale cost of this amount is about US$6.20.^[4] In 2017, it was the 301st most commonly prescribed medication in the United States, with more than one million prescriptions.^[5]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Cilostazol Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 23 March 2019.
^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 9 September 2020.
^ ^a ^b ^c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 231–232. ISBN 9780857113382.
^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
^ "Cilostazol - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

[AHFS2019-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Cilostazol Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 23 March 2019.

[WHO2020DDD-2] "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 9 September 2020.

[BNF76-3] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 231–232. ISBN 9780857113382.

[NADAC2019-4] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.

[ref-5] "Cilostazol - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

[1]

[3]

[4]

[5]